Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785908 | 0.82 | HRH3 (0.62) | HRH3DRD2 | |
| SCHEMBL5790050 | 0.82 | HRH3 (0.62) | HRH3DRD2 | |
| SCHEMBL5786321 | 0.81 | HRH3 (0.58) | HRH3 | |
| SCHEMBL5788733 | 0.79 | HRH3 (0.58) | HRH3DRD4 | |
| SCHEMBL31010354 | 0.78 | DRD2 (0.70) | HRH3DRD2DRD4DRD3PDE2A | |
| SCHEMBL5803085 | 0.77 | HRH3 (0.56) | HRH3DRD4 | |
| SCHEMBL5786852 | 0.77 | HRH3 (0.68) | HRH3DRD2DRD4 | |
| SCHEMBL5787550 | 0.76 | KDM4E (0.57) | HRH3DRD2 | |
| SCHEMBL5786428 | 0.76 | HRH3 (0.55) | HRH3 | |
| SCHEMBL5785958 | 0.75 | HRH3 (0.56) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | claimed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | HRH3 1/4885DRD2 107/4885DRD4 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.